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ABSTRACT
Oral chronic graft-versus-host disease (cGVHD) is a significant and serious complication following allogeneic
hematopoietic stem cell transplantation (HSCT). The purpose of this study was to characterize the distribution,
type, and extent of lesions and their correlation with patient-reported symptoms such as pain and discomfort.
The effect of time since transplantation on these measures was also assessed. Consecutive patients with oral
cGVHD referred to theCenter forOral Disease at Brigham andWomen’sHospital, Boston,MA,were evaluated
over a 2-year period. Subjective data included the responses to 4 targeted symptom questions (yes/no) and a vi-
sual analog scale pain score (0-10). Objective data included the location and extent of reticulation, erythema, and
ulcerations using a previously published scoring system as well as time since HSCT. Multiple linear regression
analyses were performed using SAS.We evaluated 27 patients, for a total of 79 clinic visits (median 2, range: 1-8).
The median time since HSCT was 18 months (range: 5-157 months). The buccal and labial mucosa and tongue
were the sites of 93%of all ulcerations, 72%of all erythematous lesions, and 76%of all reticular lesions, andwere
the most frequently affected sites. The gingiva, floor of mouth, and hard and soft palate were infrequently
affected. Although uncommon, ulceration of the soft palate was the objective finding most highly correlated
with increased pain (P\ .0001), and there was a generalized significant trend for increased pain scores with
increased extent of ulceration. Overall, 95% of pain scores were #5 (scale from 0-10, range: 0-7), with 40%
reporting a score of zero. However, 80% admitted to avoiding certain foods because of mouth pain. After con-
trolling for the presence and extent of ulcerations, we found that time since HSCT was inversely related to the
pain score (P\ .04). There was a statistically significant inverse relationship between the overall presence of
ulceration and time since HSCT. We found that oral cGVHD most frequently affects the buccal and labial
mucosa and the tongue. The functional impact was significant, as most patients had to restrict oral intake
because of discomfort. Both the signs and symptoms associated with oral cGVHD tend to decrease over time.
The association between ulceration of the soft palate and patient-reported pain highlights the significance of
the location of involvement and the need for targeted approaches to therapy. Our findings, in large part, support
the recently introduced National Institutes of Health response criteria for oral cGVHD, which is critical for the
conduct of effective and meaningful research in this field; however, prospective application in clinical and
investigative settings is necessary for evaluating its utility and efficacy in practice.
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Chronic graft-versus-host disease (cGVHD) is
a significant and serious complication following
allogeneic hematopoietic stem cell transplantation110(HSCT), that affects upward of 70% of patients surviv-
ing more than 100 days [1]. Typically presenting 3 to 4
months after HSCT, cGVHD develops when immu-
nocompetent donor T cells recognize putative host
Clinical Evaluation of Oral cGVHD 111tissue antigens in target organs as ‘‘foreign,’’ resulting
in an immune-mediated inflammatory response and
subsequent tissue destruction [2,3]. The skin, gastroin-
testinal tract, and liver are most commonly involved;
however, almost any tissue/organ may be affected [4].
Despite tremendous advances in prevention and man-
agement, cGVHD is the leading cause of nonrelapse
treatment-related mortality (TRM) .2 years after al-
logeneic transplantation [3,5-7].
The oral cavity is affected in .70% of individuals
who develop cGVHD [6,8]. The mucosa and/or sali-
vary glands may be affected, causing significant pain
and discomfort, dysfunction, limitation of oral intake
and nutritional deficits, and an increased risk of dental
caries and other oral infections [2,9,10]. Oral mucosal
disease has been described clinically and histopatho-
logically, with reticular (hyperkeratotic) and/or ery-
thematous (atrophic) being the most common forms,
and ulcerative lesions, typically the most painful, pre-
senting less frequently [9,11-17]. Despite aggressive
conventional and novel systemic immunomodulatory
therapies that are often effective in managing other
clinical manifestations of cGVHD, the oral cavity is
frequently refractory to treatment and may be the pri-
mary source of morbidity. In some cases, the oral
cavity is the only site of clinical involvement.
Although a number of studies have described its
various clinical and histopathologic findings, oral
cGVHD has not been characterized systematically
with respect to the location, distribution, type, and ex-
tent of lesions. Very little has been reported regarding
symptomatic findings, and importantly, to what extent
objective findings correlate with patient reported mea-
sures of disease. With respect to the subjective and
objective features of oral cGVHD, the effect of time
elapsed since HSCT has not been previously reported.
This knowledge is critical for the development and
refinement of appropriate and effective measures of
disease activity and severity.
METHODS
Consecutive patients with oral cGVHD who were
referred to the Center for Oral Disease at Brigham and
Women’s Hospital/Dana-Farber Cancer Institute,
Boston, MA, were evaluated from 2003-2005. Patients
were typically referred for either definitive diagnosis
and/or for treatment of disease not adequately man-
aged by systemic therapies alone. Standardized subjec-
tive and objective data were prospectively collected on
all patients evaluated during this period. Examinations
were performed by 1 of 2 experienced and calibrated
oral medicine specialists (N.T. or S.W.). Subjective
data included the responses (yes/no) to 4 targeted
symptom questions and a visual analog scale pain score
to report current pain (0-10). Objective data included
the location and extent of reticulation (typicallyconsidered to be least symptomatic), erythema (gener-
ally more symptomatic), and ulcerations (generally
most symptomatic; Figure 1) using a previously pub-
lished clinical scoring system, and a comprehensive
weighted mucosal disease severity score was calculated
as previously described [18]. Ulcerative lesions were
cultured for herpes simplex virus (HSV). Concurrent
immunosuppressive medications were recorded.
Because of the small sample size, nonparametric
analyses were performed with P values\.05 consid-
ered statistically significant. Descriptive statistics
were calculated to evaluate the location, type, extent,
and frequency of lesions as well as symptomatic data.
As the signs and symptoms of oral cGVHD are known
to fluctuate considerably over time, each individual
patient visit was considered as the unit of analysis;
therefore, individuals could account for multiple visits.
The association of median pain score and presence/
severity of ulcerations was investigated. Because out-
comes recorded on the same patient at different visits
might exhibit some degree of correlation (especially
for visits that are close temporally), analyses were per-
formed based on fitting linear regression models using
generalized estimating equations [19]. All statistical
analyses were performed using SAS version 9.1 (SAS
Institute, Cary, NC). This study was approved by the
institutional review board of the Dana-Farber Cancer
Institute/Harvard Cancer Center, Boston, MA.
RESULTS
Twenty-seven patients transplanted for a variety of
underlying malignancies were evaluated over the
2-year study period (Table 1). The median time since
HSCT was 18 months (range: 5-157 months). All
patients were being treated with topical therapy
(dexamethasone and/or tacrolimus rinses), and all but
one patient was taking systemic immunomodulatory
medications that included prednisone, rapamycin,
Figure 1. Oral mucosal cGVHD of the right buccal mucosa with
reticular, erythematous, and ulcerative features. The unaffected
mucosa is normal and pink.
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crolimus (median of 2 medications per patient). Mouth
pain was reported at 41% of visits, and subjects admit-
ted to having to avoid certain foods (eg, spicy and
acidic foods) because of mouth sensitivity at nearly
80% of visits (Table 2). Mouth tightness was reported
in 23% of visits (Table 2). There were no reported pain
scores.7 (scale from 0-10, range: 0-7; Table 1). Over-
all, 95% of pain scores were #5, with 40% reporting
a score of zero (data not shown). There were no
positive HSV cultures.
The presence and extent of oral lesions based on
type, extent, and location are illustrated in Tables 3
and 4. The buccal mucosa, labial mucosa, and tongue
were most frequently affected (Table 3), accounting
for 93% of ulcerations, 72% of erythematous lesions,
and 76% of reticular lesions (Table 4). The gingiva,
floor of mouth, and hard/soft palate were infrequently
affected; when involved, these sites were always associ-
ated with buccal, labial, or lingual lesions. When cor-
related with the pain score, the composite weighted
score of extent of mucosal involvement was borderline
statistically significant (Spearman correlation coeffi-
cient 0.35, P 5 .08; data not shown).
As ulcerations are considered to be the most symp-
tomatic oral lesions, we investigated the extent to
which presence and/or extent of ulcerations was asso-
ciated with pain. A significant positive relationship was
found between the presence of ulcerations and the
overall pain score (Table 5). Although the majority
of anatomic sites reached statistical significance for
Table 1. Descriptive Statistics and Pre-HSCT Diagnoses
Patients 27 (male 5 13,
female 5 14)
Patient visits 79
Median number of visits (range) 2 (1-8)
Median age (range) 44 (28-68)
Median months since transplant (range) 18 (5-157)
Median pain score (range) 1.0 (0-7)
Diagnosis n 5 27
Chronic myelogenous leukemia 10
Acute myelogenous leukemia 9
Chronic lymphocytic leukemia 3
Chronic neutrophilic leukemia 1
Hodgkin disease 1
Myelodysplastic syndrome 1
Non-Hodgkin lymphoma 1
Polycythemia vera 1
Table 2. Responses to Symptomatic Questions
Question ‘‘Yes’’ Response (%) ‘‘Yes’’
Mouth pain? 23 41
Avoid foods? 44 79
Mouth tightness? 13 23
Pain swallowing? 11 20this association, the actual range of pain scores (from
no ulcer to ulcer) was small. Although uncommonly
affected, ulceration of the soft palate (Figure 2) was
the objective finding that correlated with the greatest
level of pain (5.5 with ulcers, 1.0 without ulcers;
P \ .0001). Furthermore, a Spearman correlation
demonstrated that there was a generalized statistically
significant trend for increased pain scores with in-
creased extent of ulceration (Table 6). Twenty-two
percent (n 5 14) of visits were limited to reticular dis-
ease; in this subgroup, 86% of pain scores were zero
and none were .1; however, 64% still admitted to
having to avoid foods because of sensitivity.
As cGVHD tends to develop during a relatively
well-defined period of time, we evaluated the extent
to which time since HSCT affected the above-re-
ported outcomes, again using the presence and extent
of ulceration as a surrogate marker. There was a gener-
alized inverse relationship between the overall preva-
lence of ulcerations in the study population and time
since HSCT, with two anatomic sites reaching statisti-
cal significance (eg, soft palate, P\ .0001; data not
shown). For example, taking into account those sites
that were statistically significant (P\ .05), the median
number of months since HSCT associated with ulcers
ranged from 11 to 16, compared to 19 to 26 without
ulcers. Extent of ulceration was inversely correlated
with time since HSCT (eg, left and right buccal mu-
cosa Spearman correlation coefficients of 20.22 and
20.24, P5 .05 and .04, respectively). After controlling
for the presence and extent of ulcerations in the overall
study population, we found that time since HSCT was
inversely related to the pain score (P\ .04).
DISCUSSION
This study represents one of the largest series of
patients with oral cGVHD and the most comprehen-
sively detailed report with respect to both objective
and subjective findings. The clinical findings of distri-
bution and type of lesions were for the most part con-
sistent with previous reports. Schubert et al. [9] found
Table 3. Presence of Reticulation, Erythema, and Ulceration by Site
Reticulation Erythema Ulceration
Site Yes (%) Yes (%) Yes (%)
Labial mucosa 65 27 16
Left buccal mucosa 87 63 56
Right buccal mucosa 84 59 49
Maxillary gingiva 39 28 0
Mandibular gingiva 35 19 1
Dorsal tongue 75 19 14
Ventral tongue 61 30 39
Floor of mouth 5 1 3
Hard palate 32 22 6
Soft palate 8 6 4
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Site Erythema Ulceration
(%) #1 cm2 1-3 cm2 $3 cm2 Total % #1 cm2 1-3 cm2 $3 cm2 Total %
Labial mucosa 7.8 1.8 0 9.7 6.0 2.7 0 8.7
Left buccal mucosa 15.2 5.1 2.8 23.0 18.1 7.4 4.0 29.5
Right buccal mucosa 12.9 6.9 1.8 21.7 10.1 8.1 8.1 26.2
Maxillary gingiva 7.4 0.5 2.3 10.1 0 0 0 0
Mandibular gingiva 5.1 1.4 0.5 6.9 0.7 0 0 0.7
Dorsal tongue 5.5 1.4 0 6.9 6.7 0.7 0 7.4
Ventral tongue 8.8 2.3 0 11.1 12.8 4.0 4.0 20.9
Floor of mouth 0.5 0 0 0.5 1.3 0 0 1.3
Hard palate 4.2 3.7 0 7.8 2.0 0.7 0.7 3.4
Soft palate 1.8 0.5 0 2.3 0 1.3 0.7 2.0
Total % 69.1 23.5 7.4 100 57.7 24.8 17.5 100
Extent of reticulation not reported as only recorded as present/not present.that both erythema (73%) and lichenoid reticulation
(36%) of the buccal and labial mucosa were common
in 33 patients with cGVHD. They also found that
ulcerative lesions were seen infrequently but most
commonly affected the buccal mucosa, palate, and
tongue dorsum, and that pain was reported in 56%
of patients but not exclusively those with ulcerations.
Busca et al. [20] followed 147 adult patients surviving
until at least day 100, and found that 71% developed
cGVHD, and of these, 54% developed oral cGVHD.
They found that 44% had erythema, 68% had lichen-
oid/reticular changes, and 26% presented with ulcera-
tions. The buccal mucosa was involved 98% of the
time followed by the tongue (30%), lips (18%), and
palate (16%). Nakamura et al. [16] found that of 18 pa-
tients diagnosed with cGVHD, 61% (n 5 11) had
lichenoid lesions on the buccal, labial, and lingual
mucosa, although extent, severity, and symptoms
were not reported.
Table 5. Association between Presence of Ulcerations and Pain Score
Site Presence of Ulcer
Median
Pain
Score
P Value
(GEE)
Labial mucosa Y 12 2.5 .22
N 61 1.0
Left buccal mucosa Y 40 2.0 .0016
N 33 0
Right buccal mucosa Y 35 2.0 .003
N 38 0
Dorsal tongue Y 10 1.5 .29
N 63 1.0
Ventral tongue Y 29 2.0 .03
N 44 0.25
Floor of mouth Y 2 3.75 \.0001
N 71 1.0
Hard palate Y 5 3.0 \.0001
N 68 1.0
Soft palate Y 3 5.5 \.0001
N 70 1.0We found that the buccal, labial, and lingual
mucosa accounted for greater than three-quarters of
all lesions, suggesting that greater emphasis should be
placed on examining these sentinel sites as part of rou-
tine surveillance of cGVHD. These data support the
recently published response criteria for oral cGVHD
(http://www.asbmt.org/GvHDForms), which includes
these sites but excludes the gingiva and floor of the
mouth, which were rarely affected [21].
Approximately 60% of ulcerative lesions were
\1.0 cm in diameter, and most frequently affected
the buccal mucosa, palate, and tongue dorsum, similar
to previous findings [9]. The National Institutes of
Health (NIH) response criteria measures ulcerations
as either not present (mild), #20% of the evaluated
mucosal surfaces (moderate), or.20% (severe). Given
our findings, very few if any patients would be scored
as ‘‘severe’’ as the ulcerations have to account for
.20% of the total mucosal surface areas evaluated.
Our data demonstrates that the presence of ulcerations
has a profound impact on the overall symptoms of
Figure 2. Ulcerative and erythematous cGVHD of the palate.
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may be present in the absence of ulcerations, as even
purely reticular lesions are associated with an underly-
ing inflammatory response and may be symptomatic.
Oral cGVHD can have a tremendous impact on
quality of life, especially with respect to one’s ability
to speak and eat. Forty-one percent admitted to having
mouth pain, compared to previous reports of 5% [20]
and 56% [9]. In contrast, 80% admitted to having to
avoid certain foods (eg, spicy, acidic, and hard/crusty
foods) because of sensitivity, indicating that mouth
discomfort was, in fact, far more prevalent with a sig-
nificant impact on oral intake. The NIH Consensus
Development Project on Criteria for Clinical Trials
in Chronic Graft-versus-Host Disease includes patient
reported outcomes (0-10 scale, most severe during the
previous week) for both mouth pain in the absence of
stimulation as well as mouth sensitivity, which is de-
fined as irritation from normally tolerated spices,
foods, liquids, and/or flavors (eg, mint toothpaste, car-
bonated drinks) [21]. We did not assess which foods
specifically were avoided, or the extent to which oral
intake was limited by oral cGVHD symptoms; there-
fore, the dietary and nutritional impacts, critical ele-
ments in the maintenance of overall health, are
unknown. Future investigations should incorporate
the NIH response criteria to more accurately and uni-
formly assess pain and its impact on function, and may
also include a more detailed assessment of the extent to
which oral intake is restricted, and specifically which
foods are avoided [22,23].
In nearly all patients, signs and symptoms of oral
cGVHD were restricted to the oral cavity and did
not extend to the posterior oropharynx or esophagus.
Very few patients reported pain when swallowing,
a symptom most likely attributable to the presence of
soft palate ulcers (Table 5). Another possible but less
likely explanation for such pain could be the presence
of superficial mucoceles on the soft palate (not re-
ported). Superficial mucoceles are common in patients
with oral cGVHD and are typically described more as
a ‘‘nuisance’’ than actually being painful [2,17,24,25].
Table 6. Spearman Correlations of Size of Ulceration with Pain Score
Size of Ulcer
versus Pain Score
Site
Spearman
Correlation Coefficient P-Value
Labial mucosa 10.16 .18
Left buccal mucosa 10.37 .01
Right buccal mucosa 10.30 .15
Dorsal tongue 10.06 .62
Ventral tongue 10.28 .10
Floor of mouth 10.22 \.001
Hard palate 10.27 \.001
Soft palate 10.35 \.0001The question of tightness was intended to evaluate
sclerotic changes. Tightness may be noted in the con-
text of inflamed mucosa and in more severe cases pal-
pable fibrotic bands of tissue in the posterior buccal
mucosa occur; a combination of both findings may
have explained the 20% ‘‘yes’’ response in this series.
cGVHD typically develops between 4 and 7
months following HSCT, and patients are treated for
extended periods of time with often unpredictable
and incomplete responses [4,23]. The median duration
of immunosuppressive therapy is 19-23 months, with
approximately 50% continuing to require therapy at
5 years, and 15% of those surviving without relapse
continuing treatment for more than 7 years [26,27].
All but one of our patients remained on systemic im-
munosuppressive therapies at 19-23 months; however,
both the size of ulcerations and pain score were in-
versely related to time since HSCT. The explanation
for this finding is unclear, although it is likely related
to the underlying pathophysiology of cGVHD (which
is still poorly understood), namely that the level of
activity tends to decrease as tolerance develops. As
most subjects were being actively treated systemically
and topically throughout the study period, it would
be difficult to explain by efficacy of treatment alone.
Our findings, in large part support the recently
introduced NIH response criteria for oral cGVHD,
which represents an important step forward for the
conduct of effective and meaningful research in this
field. Prospective application in clinical and investiga-
tive settings will be critical for evaluating its utility and
efficacy in practice. The impact and utilization of sys-
temic and localized therapies on the measures of oral
cGVHD activity over time are unknown; only with
well-designed, multicenter interdisciplinary research
will these questions begin to be answered.
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